AB11002 - Second line of treatment for GIST

• Research type

  Research Study

• Full title

  A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imatinib at 400mg as first line treatment.

• IRAS ID

  113696

• Contact name

  Micheal Leahy

• Contact email

  Michael.Leahy@christie.nhs.uk

• Sponsor organisation

  AB Science

• Eudract number

  2011-001790-41

• Clinicaltrials.gov Identifier

  NCT01694277

• REC name

  West of Scotland REC 1

• REC reference

  13/WS/0228

• Date of REC Opinion

  23 Dec 2013

• REC opinion

  Further Information Favourable Opinion